The Food and Drug Administration (FDA) has approved the Eluvia Drug-Eluting Vascular Stent System (Boston Scientific) for the treatment of peripheral artery disease.
The Eluvia stent is designed to release paclitaxel for a 1-year time frame to prevent tissue regrowth that might otherwise block the stented artery. The approval was based on findings from the IMPERIAL trial, the first superficial femoral artery head-to-head drug-eluting stent trial evaluating the safety and efficacy of Eluvia vs Zilver PTX in 465 patients across 64 sites.
Reageer